Aphria Inc. (TSX: APHA) (NYSE: APHA) was provisionally awarded the fifth cultivation lot in Germany through its subsidiary, Aphria Deutschland GmbH, or Aphria Germany. The lot was secured following a review by a German court, which affirmed the BfArM's decision. Aphria Germany has now won the maximum output from the German tender process — a total of five lots — and is the only licensed producer in Germany with permission to grow all three strains of medical cannabis approved by the BfArM. As CBD's cultural presence grows, companies with a strong media presence and the attention of celebrities and athletes seem certain to benefit.